Drugs / T-cell Receptor-engineered T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06094842 | Apr 2025 → Mar 2028 | prostate small cell carcinoma | Fred Hutchinson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-cell Receptor-engineered T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06094842 ↗ |
| Route | Intravenous | “Given autologous L1CAM-specific CAR+EGFRt+ T cells IV” NCT06094842 ↗ |